Urgent.News

What's breaking now, across thousands of outlets.

AI

STAT+: Pharmalittle: We’re reading about Sanofi eyeing Insmed, AI speeding drug development, and more

Sanofi weighs an Insmed takeover, the FDA slams J&J over misleading bladder cancer drug claims, and more pharma news:

STAT+: Pharmalittle: We’re reading about Sanofi eyeing Insmed, AI speeding drug development, and more

AI has accelerated the early-stage drug development process for major pharmaceutical companies in 2023, potentially reducing the time to bring new molecules into clinical trials by up to 50%, according to Reuters. Leaders at Bristol Myers Squibb, Novartis, Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca have shifted their focus from mundane tasks, such as regulatory filing preparation, to leveraging AI for designing molecules, assessing promising candidates, and identifying potential safety issues.

Several of the largest pharmaceutical firms have informed a Congressional committee that they do not intend to establish new clinical trial sites in China's Xinjiang region or at hospitals associated with the Chinese military. This revelation was made by the House Select Committee on China, which initiated investigations into five companies—Merck, Eli Lilly, AbbVie, Pfizer, and Bristol Myers Squibb—due to concerns about intellectual property vulnerabilities, military connections, and ethical standards at trial locations in sensitive areas of China.

Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at statnews.com →

More in AI

More from Friday 20 November →